ELTX ELICIO THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ELICIO THERAPEUTICS INC reported revenue of n/a, net income of −$8.22M and diluted EPS of −$0.43; for the fiscal year ended December 2025 revenue was n/a.
ELTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$37.7M, net income −$39.6M (margin n/a), EPS −$2.58
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$45.0M, net income −$51.9M (margin n/a), EPS −$4.25
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$35.7M, net income −$35.2M (margin n/a), EPS −$6.96
- Fiscal year ended Dec 2022: revenue $2.30M, gross profit n/a, operating income −$23.7M, net income −$28.2M (margin -1225.9%), EPS −$89.27
- Fiscal year ended Dec 2021: revenue $28.3M, gross profit n/a, operating income −$39.3M, net income −$54.6M (margin -192.8%), EPS −$1.93
ELTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$8.22M, EPS −$0.43
- Quarter ended Mar 31, 2026: revenue n/a, net income −$11.8M, EPS −$0.65
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$7.72M, EPS −$0.45
- Quarter ended Sep 30, 2025: revenue n/a, net income −$10.1M, EPS −$0.60
- Quarter ended Jun 30, 2025: revenue n/a, net income −$10.6M, EPS −$0.66
- Quarter ended Mar 31, 2025: revenue n/a, net income −$11.2M, EPS −$0.87
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$14.0M, EPS −$1.07
- Quarter ended Sep 30, 2024: revenue n/a, net income −$18.8M, EPS −$1.39
- Quarter ended Jun 30, 2024: revenue n/a, net income −$7.23M, EPS −$0.64
- Quarter ended Mar 31, 2024: revenue n/a, net income −$11.8M, EPS −$1.15
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$8.95M, EPS $21.69
- Quarter ended Sep 30, 2023: revenue n/a, net income −$10.7M, EPS −$1.27
- Quarter ended Jun 30, 2023: revenue n/a, net income −$7.56M, EPS −$2.61
- Quarter ended Mar 31, 2023: revenue $0 (down 100.0% year over year), net income −$8.03M, EPS −$24.77
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0 (down 100.0% year over year), net income −$6.65M, EPS −$42.92
- Quarter ended Sep 30, 2022: revenue $0 (down 100.0% year over year), net income −$7.20M, EPS −$22.67
- Quarter ended Jun 30, 2022: revenue $653K (up 20.9% year over year), net income −$7.30M, EPS −$23.20
- Quarter ended Mar 31, 2022: revenue $1.65M (up 344.2% year over year), net income −$7.06M, EPS −$0.48
- Quarter ended Dec 31, 2021 (from the annual report): revenue $25.9M, net income $14.9M, EPS $0.74
- Quarter ended Sep 30, 2021: revenue $1.46M, net income −$15.7M, EPS −$0.53
ELTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$37.0M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$37.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$32.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$22.2M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$52.6M, share buybacks n/a
ELTX balance sheet
- Jun 30, 2026: cash $23.5M, total assets $31.3M, total liabilities $23.4M, shareholders' equity $7.94M, long-term debt $9.54M
- Mar 31, 2026: cash $14.9M, total assets $22.7M, total liabilities $24.1M, shareholders' equity −$1.44M, long-term debt $9.48M
- Dec 31, 2025: cash $18.6M, total assets $25.9M, total liabilities $24.2M, shareholders' equity $1.64M, long-term debt $9.41M
- Sep 30, 2025: cash $20.6M, total assets $28.3M, total liabilities $24.5M, shareholders' equity $3.82M, long-term debt $9.72M
- Jun 30, 2025: cash $22.1M, total assets $29.5M, total liabilities $27.7M, shareholders' equity $1.83M, long-term debt $9.34M
- Mar 31, 2025: cash $18.4M, total assets $28.1M, total liabilities $19.2M, shareholders' equity $8.90M
- Dec 31, 2024: cash $17.6M, total assets $28.2M, total liabilities $39.5M, shareholders' equity −$11.3M, long-term debt $20.0M
- Sep 30, 2024: cash $26.0M, total assets $38.4M, total liabilities $57.4M, shareholders' equity −$19.0M
Is ELTX profitable?
No. ELICIO THERAPEUTICS INC lost $37.8M over the last four quarters.
What is ELTX's EPS?
Diluted earnings per share over the last four quarters were −$2.13; −$0.43 in the latest quarter.